Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
08 avr. 2022 13h07 HE
|
Caribou Biosciences, Inc.
-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an expected...
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21 mars 2022 16h02 HE
|
Caribou Biosciences, Inc.
-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission...
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
08 mars 2022 20h19 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Caribou Biosciences to Present at Upcoming Investor Conferences
07 mars 2022 16h11 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
07 févr. 2022 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
18 janv. 2022 08h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences to Present at Upcoming Investor Conferences
17 nov. 2021 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h05 HE
|
Caribou Biosciences, Inc.
On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010 Expanded leadership with appointments of Ran Zheng and Dara...
Caribou Biosciences Appoints Dara Richardson-Heron, M.D., to its Board of Directors and Ruhi Khan as Chief Business Officer
08 nov. 2021 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...